Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
AUTL Stock Chart & Stats
$1.46
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.46
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.11 - $2.70
Previous CloseN/A
Volume359.61K
Average Volume (3M)2.05M
Market Cap
$380.58M
Enterprise Value$346.99M
Total Cash (Recent Filing)$367.41M
Total Debt (Recent Filing)$65.83M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Mar 10, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding266,143,280
10 Day Avg. Volume1,358,543
30 Day Avg. Volume2,048,016
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.40
Price to Sales (P/S)59.25
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue6.79
Enterprise Value/Gross Profit-2.19
Enterprise Value/Ebitda-1.38
Forecast
1Y Price Target
$7.18Price Target Upside391.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsRobust pivotal and early‑phase data for obe-cel and Aucatzyl, showing strong responses and a differentiated safety profile, support potential label expansions into pediatric ALL and lupus and broaden the drug's addressable market.
Commercial Rollout And Market ShareRapid activation of authorized treatment centers and favorable real‑world uptake, including physicians treating older patients and consistent full dosing, point to accelerating market share gains and commercial momentum.
Regulatory PositioningRMAT designation for obe-cel in pediatric patients combined with prominent scientific presentations enhances regulatory and clinical visibility, which can speed development and commercial adoption.
Bears Say
Below‑consensus GuidanceCompany guidance that fell below analyst and Street expectations prompted downward revisions to sales forecasts and reduced price targets, weighing on near‑term valuation.
Margin Pressure From CostsHigher‑than‑expected cost of goods sold relative to sales puts pressure on gross margins and could postpone profitability until pricing or manufacturing efficiencies are achieved.
Reimbursement And Patient FlowChanges in CMS reimbursement have slowed patient referrals and flattened sales, creating risk that commercial uptake will lag earlier expectations.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.10 and its highest was $2.70 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $380.58M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Mar 10, 2026 which is in 25 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Nov 12, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.086.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.25.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,143,280 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went down -9.333%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.18 (391.78% Upside)
$7.18 (391.78% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 147.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.07%
12-Months-Change
Fundamentals
Return on Equity
-60.52%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company has seen a successful launch of Obe-cel in the U.S. with significant market penetration and expansion into new clinical areas, financial challenges such as high cost of sales and increased operational losses present notable challenges. However, the company is well-capitalized to continue its growth and expansion strategies.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$7.18
▲(391.78% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.51% Mutual Funds
0.20% Other Institutional Investors
98.63% Public Companies and Individual Investors